On July 05, 2016 , the USPTO issued U.S. Patent Number 9,381,344 to EndoStim, Inc., which was successfully prosecuted by Novel IP.
The '344 patent is directed towards systems and methods for treating gastroesophageal reflux disease (GERD) includes minimally invasively implanting a stimulating device in a patient's esophagus in the region proximate the lower esophageal sphincter (LES). The patient is provided with a questionnaire related to his disease via an online service. The questionnaire is accessed on a mobile device, such as a cell phone, or on a computer with network access. The data from the sensors and the answers from the questionnaire are analyzed together by a health care provider using the online service. The data and answers are used to program the stimulating device, via the mobile device or computer, to optimize treatment.
Independent Claim 1 describes " A method of treating gastrointestinal reflux disease in a patient, comprising implanting a device, having a plurality of dimensions, wherein the device is implanted such that the device is oriented between 45 degrees and 135 degrees within a standing patient in relation to a ground surface and wherein the device comprises a housing; a stimulator enclosed within the housing; a plurality of electrodes wherein said electrodes are attached to the outer surface of the housing using conductors at least 1 mm in length wherein the electrodes are attached to the housing by insulated conductors; and a controller configured to electrically generate, and transmit, an electrical pulse train to the LES through the plurality of electrodes, wherein the electrical pulse train is defined by a pulse width in a range of 30 μsec to 5 msec, a pulse amplitude in a range of 2 to 15 mAmp, and a pulse frequency in a range of 2 to 80 Hz; and positioning the plurality of electrodes to be at least 1 mm from the patient's main vagal trunk, to be at least 1 mm from the patient's cardiac tissue and to be in electrical communication with the patient's lower esophageal sphincter (LES). "